Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 16/20 | 1.00 |
| ▸ | GRM6 | O15303 | 13/20 | 1.00 |
| ▸ | GRM3 | Q14832 | 13/20 | 1.00 |
| ▸ | GRM5 | P41594 | 4/20 | 1.00 |
| ▸ | GRM4 | Q14833 | 4/20 | 1.00 |
| ▸ | GRM1 | Q13255 | 3/20 | 1.00 |
| ▸ | GRM8 | O00222 | 6/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13319986 | 0.82 | GRM1 (1.00) | GRM2GRM6GRM3GRM5GRM4 | |
| SCHEMBL6738759 | 0.82 | GRM1 (1.00) | GRM2GRM6GRM3GRM5GRM4 | |
| SCHEMBL8425584 | 0.72 | GRM2 (0.56) | GRM2GRM6GRM3GRM5GRM4 | |
| SCHEMBL8425583 | 0.72 | GRM2 (0.56) | GRM2GRM6GRM3GRM5GRM4 | |
| SCHEMBL10577620 | 0.70 | GRM1 (0.62) | GRM2GRM6GRM3GRM5GRM4 | |
| SCHEMBL670022 | 0.70 | GRM1 (0.62) | GRM2GRM6GRM3GRM5GRM4 | |
| SCHEMBL25660648 | 0.70 | GRM1 (0.62) | GRM2GRM6GRM3GRM5GRM4 | |
| SCHEMBL10621923 | 0.69 | GRM2 (0.53) | GRM2GRM6GRM3GRM5GRM4 | |
| SCHEMBL21983822 | 0.68 | GRM2 (0.52) | GRM2GRM6GRM3GRM5GRM4 | |
| SCHEMBL2562686 | 0.67 | GRM2 (0.50) | GRM2GRM6GRM3GRM5GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609721-B2 | Ligands for metabotropic glutamate receptors and inhibitors of NAALADase | GEORGETOWN UNIVERSITY (US) | 2013-12-17 | — | — | US | disclosed |
| US-20080176821-A1 | LIGANDS FOR METABOTROPIC GLUTAMATE RECEPTORS AND INHIBITORS OF NAALADASE | GEORGETOWN UNIVERSITY | 2008-07-24 | — | — | US | disclosed |
| US-6528499-B1 | Ligands for metabotropic glutamate receptors and inhibitors of NAALADase | GEORGETOWN UNIVERSITY | 2003-03-04 | — | — | US | disclosed |
| US-6479470-B1 | NAAG AND NAALADASE HAVE BEEN IMPLICATED IN SEVERAL PATHOLOGICAL CONDITIONS RELATING TO GLUTAMATE ABNORMALITIES AND NEUROTOXICITY | GEORGETOWN UNIVERSITY | 2002-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176821-A1 | LIGANDS FOR METABOTROPIC GLUTAMATE RECEPTORS AND INHIBITORS OF NAALADASE | GRM3, GRM2, GRM1 | GRM2 2/4885GRM6 9/4885GRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.